Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

This study compares a generic version of imatinib (brand name Carcemia®) to the original branded imatinib (Glivec®) in treating newly diagnosed chronic myeloid leukemia (CML) — a blood cancer — in its chronic (early) phase. The goal is to confirm the generic works just as well in everyday clinical practice. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with CML in its chronic phase, confirmed by a Philadelphia chromosome test - Your diagnosis was made within the last 3 months - You have not yet started treatment for CML **You may NOT be eligible if...** - Your CML has already advanced to a more aggressive phase (accelerated or blast phase) at enrollment - You have conditions that contraindicate imatinib per its official prescribing information Talk to your doctor to see if this trial is right for you.